Click here to view online. Add this email to your safelist.

AstraZeneca logo

Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

18 September 2018

74% of continuously-treated patients with a blood eosinophil count of 300 or greater were exacerbation-free in the second year of treatment Data presented at the European Respiratory Society (ERS) International Congress 2018

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2018

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.